Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2022-06-12 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
立信会计师事务所（特殊普通合伙）关于上海美迪西生物医药股份有限公司向特定对象发行股票申请文件的审核问询函之回复报告
Capital/Financing Update Classification · 95% confidence The document is a detailed response report to an inquiry letter from the Shanghai Stock Exchange regarding a specific stock issuance application by Shanghai Medicilon Inc. It contains extensive financial and project investment details, including breakdowns of investment amounts, equipment purchases, and justifications for the financing scale. The document references a specific regulatory inquiry (审核问询函) related to a stock issuance application and provides detailed explanations and data supporting the application. This type of document is typical of filings related to capital raising activities and financing updates, specifically related to a company's issuance of shares to specific investors. It is not an annual report, earnings release, or audit report, but rather a detailed capital/financing update responding to regulatory questions about the issuance and use of funds. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content depth support this classification with high confidence.
2022-06-12 Chinese
美迪西：关于公司2022年度向特定对象发行A股股票预案修订情况说明的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shanghai Medicilon Inc. regarding revisions to its 2022 plan for a private placement of A shares. It details updates to the share issuance plan, including changes in the number of shares to be issued, shareholder meeting approvals, and related financial and regulatory information. The document does not contain full financial statements or comprehensive financial performance data but focuses on the capital raising plan and its adjustments. This fits the category of Capital/Financing Update (CAP), as it relates to company fundraising activities and changes in capital structure. The document length is about 2057 characters, which is consistent with an announcement rather than a full report. Therefore, the classification is CAP with high confidence.
2022-06-12 Chinese
美迪西：2022年度向特定对象发行A股股票方案的论证分析报告（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Shanghai Medicilon Inc. regarding a 2022 plan for a private placement of A shares to specific investors. It discusses the background, purpose, necessity, pricing, and regulatory compliance of the share issuance. The content includes extensive financial data, market analysis, regulatory references, and detailed explanations of the issuance process and its impact on earnings per share. The document is lengthy (15,000 characters) and contains substantive financial and business information related to capital raising. It is not a brief announcement or a certification but a comprehensive report on a capital financing activity. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2022-06-12 Chinese
美迪西：2022年度向特定对象发行A股股票募集资金使用可行性分析报告（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集资金使用可行性分析报告 (修订稿)" which translates to "Feasibility Analysis Report on the Use of Raised Funds (Revised)" for a specific issuance of A shares in 2022. It details the planned use of funds raised from a targeted share issuance, including investment projects and supplementary working capital. The document includes detailed investment plans, project descriptions, feasibility studies, and the impact of the fund usage on the company's financial and operational status. It is not a full annual or interim financial report, nor is it an announcement of voting results or a regulatory filing. It is a detailed capital/financing update related to the company's fundraising activities and the use of proceeds from a specific share issuance. The document length is over 6,000 characters and contains substantive content about the capital raising and fund usage plan. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-06-12 Chinese
美迪西：2022年度向特定对象发行A股股票预案（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled "2022 年度向特定对象发行 A 股股票预案 (修订稿)" which translates to "2022 Annual Proposal for Private Placement of A Shares" by Shanghai Medicilon Inc. It details a plan for a private placement of shares to specific investors, including the number of shares, pricing methodology, use of proceeds, and regulatory approvals required from the Shanghai Stock Exchange and China Securities Regulatory Commission. The document includes extensive discussion on the issuance plan, pricing, investor restrictions, use of funds, risk disclosures, and board approvals. This is a detailed capital raising plan and proposal document, not a simple announcement or a report of results. It is not an earnings release, annual report, or management discussion. It is clearly an update on capital raising activities and issuance of new shares to specific investors. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is a full proposal, not just an announcement or regulatory filing. Confidence is high given the explicit focus on share issuance and fundraising.
2022-06-12 Chinese
上海美迪西生物医药股份有限公司2022年度向特定对象发行A股股票募集说明书（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集说明书" which translates to a "Prospectus" or "Offering Circular" for a specific issuance of A shares by Shanghai Medicilon Inc. in 2022. It contains detailed information about the company, its shareholders, industry background, regulatory environment, and the specifics of the share issuance. This type of document is related to capital raising activities and provides comprehensive details about the financing event. It is not an annual report, earnings release, or management discussion, but rather a detailed capital/financing update document. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the full document, not just an announcement of a report publication.
2022-06-12 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.